Evidence map›Paper›PMID 31010714›Full record

ArticleVaccine2019

Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease.

Diane M Da Silva, Joseph G Skeate, Elena Chavez-Juan, Kim P Lühen, Jiun-Ming Wu, Chia-Mao Wu, W Martin Kast, KinKai Hwang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Cervical Cancer Immunotherapy: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Review
  15. Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus.Environmental science and pollution research international · 2021
    Review
  16. Review
  17. Article
  18. Review
  19. Advances in immunotherapy for cervical cancer.Current opinion in oncology · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Diane M Da SilvaDepartment of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA 90033, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. Electronic address: Diane.DaSilva@med.usc.edu.
Joseph G SkeateDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Elena Chavez-JuanNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Kim P LühenNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Jiun-Ming WuTheVax Genetics Vaccine Co., Ltd, Zhubei City, Hsinchu County 302, Taiwan, ROC.
Chia-Mao WuTheVax Genetics Vaccine Co., Ltd, Zhubei City, Hsinchu County 302, Taiwan, ROC.
W Martin KastDepartment of Obstetrics & Gynecology, University of Southern California, Los Angeles, CA 90033, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA; Department of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
KinKai HwangTheVax Genetics Vaccine Co., Ltd, Irvine, CA 92618, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
VLP VACCINES AGAINST HPV INDUCED TUMORSR01CA074397 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAST, WIJBE MARTIN · 1997 to 2020
$5.5M
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA074397
6 · The paper itself

Abstract

Persistent human papillomavirus (HPV) infection is causally linked to the development of several human cancers, including cervical, vulvar, vaginal, anal, penile, and oropharyngeal cancers. To address the need for a therapeutic vaccine against HPV-associated diseases, here we test and compare the immunogenicity and therapeutic efficacy of a bacterial exotoxin fusion protein covalently linked to the HPV16 E7 oncoprotein adjuvanted with CpG or GPI-0100 in the C3.43 preclinical HPV16-transformed tumor model. We show that TVGV-1 protein vaccine adjuvanted with either CpG or GPI-0100 adjuvant induces a high frequency of E7-specific CD8

Indexed as

AnimalsFemaleHuman papillomavirus 16HumansImmunophenotypingMiceMice, Inbred C57BLPapillomavirus E7 ProteinsPapillomavirus InfectionsPapillomavirus VaccinesSaponinsGPI0100oncogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsPapillomavirus VaccinesSaponinsCpG adjuvantGPI-0100 adjuvantHPV16-induced tumorsHuman papillomavirusTherapeutic vaccine

Identifiers

PMID31010714
PMCPMC6586561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.